US 11,869,186 B2
Non-invasive determination of likely response to combination therapies for cardiovascular disease
Andrew J. Buckler, Boston, MA (US); Ulf Hedin, Ronninge (SE); Ljubica Matic, Solna (SE); and Matthew Phillips, Boston, MA (US)
Assigned to Elucid Bioimaging Inc., Boston, MA (US)
Filed by Elucid Bioimaging Inc., Boston, MA (US)
Filed on Jun. 10, 2022, as Appl. No. 17/838,140.
Application 17/838,140 is a continuation in part of application No. 17/693,229, filed on Mar. 11, 2022.
Claims priority of provisional application 63/209,164, filed on Jun. 10, 2021.
Prior Publication US 2022/0409160 A1, Dec. 29, 2022
Int. Cl. G06T 7/00 (2017.01); A61B 5/055 (2006.01); G16B 5/00 (2019.01); G16C 20/30 (2019.01); G16H 20/00 (2018.01)
CPC G06T 7/0012 (2013.01) [A61B 5/055 (2013.01); G16B 5/00 (2019.02); G16C 20/30 (2019.02); G16H 20/00 (2018.01); G06T 2207/10088 (2013.01); G06T 2207/30101 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A method of providing a recommendation of a combination of any two or more therapies selected from a lipid-lowering therapy, an anti-inflammatory therapy, and an anti-diabetic therapy, for a patient diagnosed with atherosclerotic cardiovascular disease, the method comprising:
receiving non-invasively obtained data related to a plaque from the patient;
accessing a systems biology model of atherosclerotic cardiovascular disease, wherein
(i) the systems biology model represents a plurality of pathways associated with atherosclerotic cardiovascular disease,
(ii) the plurality of pathways include pathways corresponding, respectively, to all three of:
a) one or more of glycosylated low-density lipoprotein (glyLDL), oxidized low-density lipoprotein (oxLDL), and minimally-modified low-density lipoprotein (mmLDL), or very-low-density lipoprotein (VLDL),
b) one or more of Interleukin-1 (IL-1), Interleukin-1 beta (IL1β), Tumor Necrosis Factor (TNF), Interleukin-12/23 (IL12/23), Interleukin-17 (IL17), or other cytokine molecule, and
c) one or more of Mammalian Target of Rapamycin (MTOR), Nuclear Factor kappa B-1 (NFκβ1), Intercellular Adhesion Molecule 1 (ICAM1), or Vascular Cell Adhesion Molecule 1 (VCAM1), and
(iii) the systems biology model includes a disease-associated molecule level for each molecule in the systems biology model;
updating the systems biology model using personalized molecule levels derived from the non-invasively obtained data from the patient to generate a patient-specific systems biology model;
updating the patient-specific systems biology model with information relating to an effect on low-density lipoprotein (LDL) levels by a lipid lowering agent, inflammation levels by an anti-inflammatory agent, and glucose levels by an anti-diabetic agent, based on known mechanisms of action of each of the agents;
simulating a therapeutic response by the patient to a combination of any two or more of the lipid lowering agent, the anti-inflammatory agent, and the anti-diabetic agent in the updated patient-specific systems biology model to obtain simulated therapeutic effects for two or more combinations;
comparing the updated patient-specific systems biology model with and without the simulated therapeutic effects for each of the two or more combinations; and
based on the comparison, providing a report recommending for the patient a combination of therapeutic agents.